Mr. Ruane, age 47, is a dedicated pharmaceutical executive who most recently led the transformation of Tekmira Pharmaceuticals Corporation, a publicly-traded company, into a leader in the development of RNA interference (RNAi)-based pharmaceuticals. With more than 24 years experience in the biopharmaceutical industry, Mr. Ruane has successfully partnered a significant number of therapeutic products and brings strong skills in business development, commercial operations, marketing, as well as public market expertise.